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Abstract
Background & Aims: Understanding immune protection against hepatitis C virus 
(HCV) infection is necessary for designing an effective vaccine. A number of 
broadly-reactive, neutralizing antibodies have been isolated from B cells of HCV-
infected subjects. However, it remains unclear whether B cells producing such 
antibodies contribute to the clearance and long-term immune protection against 
HCV.
Methods: We analysed the B-cell repertoire of thirteen participants from the 
Amsterdam Cohort Study among injecting drug users with a median follow-up of 
17.5 years. Five subjects ultimately became chronically infected either after 
primary infection or after reinfection. Eight subjects, at the end of study follow-up, 
were HCV RNA negative following spontaneous clearance of one or multiple 
infections. From each subject, 10,000 CD27+IgG+ B cells, collected 0.75 year 
after HCV infection, were cultured to characterize the antibody repertoire.
Results: Using a multiplex flow cytometry-based assay to study the antibody 
binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-
genotype antibodies was associated with spontaneous clearance of one or 
multiple infections (p-value=0.03). Epitope specificity of these cross-genotype 
antibodies was determined by alanine mutant scanning in four subjects, who 
were HCV RNA negative following spontaneous clearance of one or multiple 
infections. Interestingly, the cross-genotype antibodies were mainly AR3-specific 
and showed cross-neutralizing activity against HCV. In addition to AR3 
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antibodies, three subjects developed antibodies recognizing AR4 of which one 
monoclonal antibody showed cross-neutralizing capacity.
Conclusions: Together, these data suggest that a strong B-cell response 
producing cross-genotype and neutralizing antibodies, especially targeting AR3, 
contribute to HCV clearance and long-term immune protection against HCV.
Lay summary
Although effective treatments against hepatitis C virus (HCV) are available, 
500,000 people die from liver disease caused by HCV each year and 
approximately 1.75 million people are newly infected which could be prevented 
by a vaccine.
For the design of such vaccine, more insight in the role of antibodies in the 
protection against HCV infection is needed.
In a cohort of injecting drug users, we found that antibodies interfering with virus 
cell entry and recognizing multiple HCV genotypes, conferred long term 
protection against developing chronic HCV infection.
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Introduction
Hepatitis C virus (HCV) is one of the major global public health problems, with 
worldwide 71 million chronically infected people, which results in 350,000 to 
500,000 liver-related deaths per year [1]. Current 'direct-acting antiviral' (DAA) 
treatment is very effective in clearing infection [2]. However, despite high DAA 
efficacy, treatment alone is unlikely to eliminate HCV by the year 2030 as 
envisioned by the WHO [1], since treated subjects may become re-infected if 
exposure continues. Moreover, worldwide, most of the HCV-infected subjects are 
unaware of their HCV status because of the prolonged asymptomatic nature of 
HCV infection and limited access to diagnostic tests [3]. In addition, as a result of 
the high cost of treatment, a large proportion of the HCV-infected subjects are left 
untreated [3]. Therefore, for the global elimination of HCV, a preventive vaccine 
is urgently needed.
Development of a protective vaccine against HCV seems feasible, since 
spontaneous clearance of the virus without antiviral therapy occurs in 25 to 40% 
of individuals after primary infection [4] and in 30 to 60% of those who are 
reinfected following clearance of a primary infection [5]. While clearance of HCV 
infection has been associated with strong and broad T cell responses [6,7], little 
is known about the role of antibodies in spontaneous clearance of HCV infection 
and protection upon re-exposure.
HCV clearance has been associated with a neutralizing antibody response 
against HCV E1E2 glycoproteins during the early phase of infection [8,9]. In 
addition, a number of broadly neutralizing antibodies have been isolated from B 
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cells of chronically infected subjects. In general, they target one of three epitopes 
which are located in or around the CD81 binding site: epitope I (amino acids 412-
423), epitope II (amino acids 434-446) and domain B (amino acids 523-535) [10-
12]. Interestingly, broadly neutralizing antibodies targeting epitope I or epitope II 
(AP33, HC84.26) protected humanized mice against HCV genotype 1b infection 
[13,14]. It has also been shown that AR3A and AR3B antibodies targeting both 
epitope II and domain B, jointly referred to as antigenic region 3 (AR3), protected 
mice against HCV infection from isolate H77 (genotype 1a) and isolate J6 
(genotype 2a) in combination with AR4A, an antibody recognizing antigenic 
region 4 (AR4) [15-17]. It remains, however, unanswered whether such broadly 
neutralizing antibodies contribute to spontaneous clearance and long-term 
immune protection in humans with ongoing exposure.
The Amsterdam Cohort Study (ACS) among drug users (DU), is a prospective 
cohort study investigating HIV and HCV infections with regular collection of 
serum, peripheral blood mononuclear cells (PBMC), and socio-demographic and 
risk behavioural data [18]. The ACS-DU cohort started in 1985 and came to an 
end in 2016 which makes it a unique cohort with one of the longest follow-up of 
DU worldwide [19]. Importantly, all ACS-participants who are injecting drug users 
(IDU) are, most likely, frequently (re-)exposed to HCV, since 65% reported at 
least weekly injecting drug use at enrolment in the cohort, with a baseline HCV 
antibody prevalence of 82% and an incidence of up to 28 primary infections per 
100 person-years among IDU [20]. Such a well-characterized cohort of highly 
exposed subjects with a long follow-up presents a unique opportunity to study the 
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role of broadly neutralizing antibodies in the spontaneous clearance of HCV 
infection and protection upon re-exposure.
Here, we studied the frequency, cross-reactivity and epitopes of HCV E1E2 
specific antibodies produced by memory B cells from ACS participants. We found 
that the frequency of HCV specific cross-genotype antibodies, targeting mainly 
the antigenic region 3 (AR3) and antigenic region 4 (AR4), was associated with 
spontaneous clearance of one or multiple HCV infection(s) and absence of HCV 
RNA at the end of the study period.
Material and methods
Subjects
Subjects were selected from the ACS-IDU. After signing a written informed 
consent, ACS participants visited the Amsterdam Health Service every 4 to 6 
months, where blood was drawn for laboratory testing, PBMCs were stored and 
where they completed a standardized questionnaire on risk behaviour [18]. Our 
study relies in part on self-reports, which have been shown to be a valid method 
for measuring behavioural variables in our cohort, where social desirability does 
not play an important role [21].
For the study presented here, out of 106 subjects with an acute or recent HCV 
infection we selected those with at least 5-year follow-up after primary infection 
with available PBMCs. Acute primary infection was defined by seroconversion for 
HCV antibodies (AxSym HCV version 3.0; Abbott) during follow up [22]. Recent 
infection was assumed when at cohort entry HCV antibodies were already 
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present in subjects who had started injecting drugs less than two years before. 
We excluded subjects who were HIV-seropositive or positive for HBV surface 
antigen (AxSym HBsAg, Abbott) at the time of HCV infection.
For seroconverters, the date of the infection was estimated by calculating the 
midpoint between the last HCV seronegative visit and the first HCV seropositive 
visit. The date of infection for the recent infections was estimated as the midpoint 
between the start of injecting drugs and cohort entry [22].
HCV viremia was determined for these subjects at yearly intervals using a 
transcription-mediated amplification assay with a detection limit of 5 IU/ml 
(Versant; Siemens Medical Solutions Diagnostics). If HCV RNA was detected, 
genotyping was performed by sequencing the NS5B region [23]. Clearance was 
defined as being HCV RNA negative at two subsequent time points. After 
clearance, in some subjects, reinfection was documented, as evidenced by at 
least one HCV RNA positive time point during follow-up following clearance of an 
earlier infection. Chronic infection was defined as continuous viremia for at least 
two years after the estimated date of (re)infection. This study was approved by 
the Medical Ethical Committee of the AMC and informed consent was obtained 
from all subjects. HCV genotype, HBV status and HIV status are summarized in 
Supplementary Table 1.
B cell isolation and cultures
From ACS participants, frozen PBMC were obtained and CD27+IgG+ B cells 
were immortalized as described previously [24]. In brief, B cells were isolated 
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and, after stimulation, the cells were transduced with a retroviral vector 
containing the transgenes BCL6, BCL-xL and green fluorescent protein as 
marker gene. Transduced B cells were maintained in culture with gamma-
irradiated CD40 Ligand expressing L-cells and recombinant mouse interleukin-
21. The transduced B cells secrete immunoglobulins (antibodies) into the culture 
supernatant.
Multiplex flow cytometry assay
To determine the breadth of the antibodies, we performed a multiplex flow 
cytometry assay as described previously [25]. In brief, antibodies present in B 
cell supernatants were incubated with a mix of fluorescently barcoded 293T/17 
cells (ATCC) transfected with full-length E1E2 derived from six HCV genotypes 
(Supplementary material and methods). After addition of the secondary 
polyclonal goat anti-human IgG-PE antibody (Southern Biotech), the 
fluorescence was measured using a FACSCantoTM II flow cytometer (BD 
Biosciences). To determine E1E2 antibody binding, the value obtained for 
binding to E1E2 transfected cells was subtracted from the value obtained for 
binding to non-transfected cells and normalized by using the average of the 
seven negative antibody controls. The cut-off value for binding was based on 
values of 882 B cell supernatants from three HCV uninfected subjects 
(Supplementary Fig. 1, Supplementary material and methods).
Enzyme-linked immunosorbent assay (ELISA)
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To determine the binding characteristics of the antibodies, ELISA assays were 
performed as described previously [26]. In brief, plates were coated either with 
the HIS-tagged E2 ectodomain (Supplementary material and methods) or with 
Galanthus nivalis lectin on which E1E2 protein containing 293T/17 cell lysate 
was captured. Then, antibodies present in B cell supernatant were added and 
binding was detected by horseradish peroxidase-conjugated polyclonal goat anti-
human IgG (Jackson). Optical density (OD) at 450nm was measured with an 
EnVision Multilabel Reader (PerkinElmer).
HCV pseudoparticle (pp) neutralization
Neutralization activity of antibodies was determined using the HCVpp system 
based on Luciferase reporter gene activity (Supplementary material and 
methods).
HCV cell culture (cc) neutralization
Neutralization activity of antibodies was determined using the HCVcc system as 
described previously [27,28]. The detailed procedure is described in the 
supplementary material and methods. 
Antibody sequencing
The variable regions of the antibody heavy and light chain from the cross-
genotype B cells were sequenced as described previously [29]. In brief, total 
RNA was isolated from B cells and after generation of cDNA, the cDNA from the 
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heavy and light chain were specifically amplified by polymerase chain reaction. 
Finally, the sequences were obtained by Sänger sequencing using BDT reagents 
(Thermo Fisher Scientific) and were submitted to the IMGT/V-QUEST database 
to assess V(D)J usage and somatic hypermutation status [30].
Data analysis
Data were analysed using Prism software (GraphPad). Statistical comparison 
between categories was performed using an one-tailed Mann–Whitney test, as 
we hypothesized that cross-genotype antibodies were more frequently present in 
subjects who spontaneously cleared infection(s) (software package SPSS, v. 
19.09, IBM). Flow cytometry data were analysed using FlowJo software (FlowJo).
Results
Characteristics of the study population.
Thirteen cohort participants with acute or recent HCV infection met the inclusion 
criteria for this study. The median age of the selected subjects was 29 years 
(interquartile range (IQR) 23 - 33) at the time of HCV infection (Table 1). The 
median follow-up time of these subjects since primary HCV infection was 17.5 
years (IQR 11.7 - 18.9). The subjects were classified into two groups based on 
the outcome of HCV infection:
(i) subjects who became chronically infected (CHRs; n = 5) either after 
primary infection (CHR1-3), or after HCV reinfection (CHR 4-5);
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(ii) subjects who cleared one or more infections and were HCV RNA 
negative at the end of follow-up (CL1-8). All subjects who cleared the infection 
were presumably re-exposed to HCV as they continued injecting drugs for a 
median of 5.9 years after primary infection during a time period (1986-1994) of 
extremely high HCV incidence (10 - 28 per 100 person-years) in this cohort [20]. 
Frequent re-exposure was also evidenced by the occurrence of one or more 
reinfections, which were documented in eight of thirteen subjects. Characteristics 
of all thirteen subjects are summarized in Table 1.
High frequencies of cross-genotype antibodies in CLs
From each subject, 7 to 15 millions PBMC were available that had been collected 
0.75 year (IQR 0.54 – 1.12) after HCV infection (Table 1). From these PBMC, 
CD27+IgG+ B cells were purified and subsequently immortalized [24]. A total of 
10,290 cells per subjects were cultured as mini-cultures at a density of 35 B cells 
per well. Antibodies secreted in the B cell supernatant were analysed for binding 
to 293T cells transfected with full-length E1E2 from HCV genotypes 1a, 2b, 3a, 4, 
5 and 6, using the multiplexed flow cytometry assay as described before [25].
At a density of 35 cells per well, the percentage of positive wells was below or 
equal to 37%. We, therefore, assumed based on the Poisson’s distribution, that 
only one out of the 35 cells produced E1E2 specific antibodies. The median 
frequency of E1E2 specific antibodies in the B-cell repertoire was 14.6 antibodies 
per 10,000 CD27+IgG+ B cells for CHRs (IQR 3.9 - 18.5) and 16.5 antibodies per 
10,000 CD27+IgG+ B cells for CLs (IQR 3.6 - 77) (Fig. 1A). Although the 
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frequencies did not differ between the groups, the antibodies from CHRs were 
mainly genotype-specific and directed against the genotype of the ongoing 
infection. This confirmed findings by Tarr et al., who described the relationship 
between serum antibody reactivity and genotype of infection [31]. Antibodies 
from CLs showed a much broader reactivity as compared to CHR derived 
antibodies. The absolute number of antibodies recognizing at least three or more 
genotypes was significantly higher in CLs as compared to CHRs (CLs:13 (IQR 
2.2 - 53.0) versus CHRs: 0 (IQR 0 – 1.9), p = 0.03, Fig. 1B and Supplementary 
Fig. 2). Three out of eight CLs had antibodies that recognized all six HCV 
genotypes with a median frequency of 3.9 per 10,000 CD27+IgG+ B cells (IQR 
3.4 - 14.6). Such broadly reactive antibodies were not detected in CHRs.
Cross-genotype antibodies from CLs predominantly target AR3.
To further characterize cross-genotype antibodies from CLs, we selected 113 B 
cell cultures from CL1, CL2, CL3, and CL7, who had the highest frequency of 
cross-genotype antibodies (Supplementary Fig. 3). To determine the epitopes 
targeted by these antibodies, we tested the antibodies secreted in the B cell 
supernatant by ELISA for binding to E2 alanine mutants in the four epitopes 
known to be recognized by broadly neutralizing HCV antibodies. Twelve alanine 
mutants were generated with mutations in epitope I (L413, G418 and W420), in 
AR3 / epitope II (L441, F442 and Y443), in AR3 / domain B (W529, G530 and 
D535) and in AR4 (R657, L692 and D698) [16,32,33]. Epitope specificity was 
determined by measuring the reduction in antibody binding to one or more 
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alanine mutants from the panel. An epitope was considered to be specifically 
recognized if an alanine mutation in that epitope resulted in more than 50% 
reduction of antibody binding compared to binding to wild-type E2.
In all four subjects, the majority of the cross-genotype antibodies (82/113, 73%) 
were specific for AR3 (Fig. 2A) as binding to the AR3-specific mutants (F442A, 
G530A and D535A) was reduced by more than 50% (Fig. 2B). Interestingly, 
binding of a subset of AR3-specific antibodies was not strongly affected by the 
alanine mutation in residue 441, which is in contrast to recent data from Gopal et 
al. who showed that this L441A mutation affected all AR3 antibodies [33]. 
Furthermore, we observed that three antibodies (C03, E17 and M11) found in 
subject CL2 were specific for an epitope shared by epitope I and AR3, as was 
evident by the loss of binding to the mutant W420A. This finding was confirmed 
at the monoclonal B cell level (Supplementary Fig. 4).
Besides antibodies specific to AR3, we observed that cross-reactive antibodies 
targeting AR4 were present in three CLs, as indicated by the decreased binding 
to the mutants R657A, L692A and D698A. Interestingly, these AR4-specific 
antibodies showed no or low binding to the soluble E2 ectodomain 
(Supplementary Fig. 5). Finally, in none of the CLs, we found antibodies that 
recognized epitope I or epitope II only.
Monoclonal cross-genotype antibodies from CLs are broadly neutralizing.
Thus far, antibody characteristics were determined using supernatants of B cells 
cultured at a density of 35 cells per well and therefore the supernatants of those 
  
16
cultures could contain 34 irrelevant antibodies. Therefore, we analysed 
antibodies at the monoclonal B cell level to study the neutralizing potency of the 
antibodies in more detail. Focusing on cross-genotype antibodies against AR3 
and AR4, thirteen mini-cultures with different alanine mutant patterns were 
selected, of which B cell clones were generated by single cell sorting 
(Supplementary material and methods). Immunoglobulin genes of AR3 and AR4 
binding B-cell clones were sequenced and ten unique antibody sequences were 
identified (Fig. 3A). In addition, two additional monoclonal antibodies (AT1706 
and AT1618) were isolated, from subject CL7 who had the highest frequency of 
cross-genotype antibodies when screening directly 5,000 CD27+IgG+ single cell 
cultures for HCVpp neutralization activity. All twelve antibodies were of the IgG1 
isotype. In addition, the majority of AR3-specific antibodies (AT antibodies 1637-
1640,1642,1643,1645) used a VH gene of the VH1.69 family. These results are 
in line with findings by us and others [15,26,34].
Next, we confirmed the cross-reactivity of the monoclonal antibodies by ELISA 
using the panel of eight E1E2 sequences from genotypes 1 to 6 (Fig. 3B). As 
expected from the mini-culture data, AT1644 and AT1645 were specific for only 
sequences from three different HCV genotypes only, whereas all other antibodies 
bound to E1E2 from genotypes 1 to 6.
The neutralization capacity of the antibodies was tested using the HCVpp system 
expressing E1E2 from genotypes 1a, 1b, 3a and 4d. These HCVpp were all 
relatively sensitive to neutralization by AR3B and AR4A (Fig. 4A). Except 
AT1644, which did not neutralize, all monoclonal antibodies neutralized at least 
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one HCVpp with ten antibodies showing broad cross-neutralization (Fig. 4B). All 
AR3-specific antibodies (AT antibodies 1637-1640,1642, 1643,1645 and 1706 - 
Supplementary Fig. 6) neutralized HCVpp with an 50% inhibitory concentration 
(IC50) range from 0.088 to 1.41 µg/mL (Fig. 4B), while the AR4-specific 
antibodies (AT1644, AT1646, AT1647 and AT1618 - Supplementary Fig. 6) had 
IC50’s above 0.1µg/mL (Fig. 4B). 
The neutralization capacity of the antibodies was further tested using a panel of 
four HCVpp which have been shown to be resistant to antibody-mediated 
neutralization (Fig. 4C) [35]. Eight out of twelve antibodies (AT antibodies 1637-
1640,1642, 1643,1618 and 1706) neutralized at least one resistant HCVpp with 
an IC50 range of 0.39 to 18.2 µg/mL (Fig. 4D). Of these antibodies, AT1640 and 
AT1618 neutralized all eight HCV isolates (Fig. 4B and Fig. 4D). Importantly, by 
examining the combined neutralization profiles of the antibodies per subject, 
antibodies from three of the four subjects tested (CL1, CL2 and CL7) covered all 
tested HCVpp.
To confirm the neutralization capacity of the antibodies, AT antibodies were 
tested at 20µg/ml for neutralization of HCVcc (isolate H77). Apart from AT1645, 
all AR3-specific antibodies (AT antibodies 1638-1640, 1643 and 1706) 
neutralized infection by more than 50% (Fig. 5A). In addition to AR3 specific 
antibodies, neutralization activity above 50% was observed for the AR4-specific 
antibody AT1618. These finding were consistent with the data obtained using 
HCVpp. 
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Since AT1618 targets AR4, and we showed that it is able to neutralize all HCVpp 
from our panel, including the resistant ones, we wanted to confirm its breadth in 
the HCVcc system using the JFH1 prototype (genotype 2) and ED43 HCV 
chimera (genotype 4a). We found that AT1618 neutralized both viruses with IC50 
‘s of 0.27 µg/ml and 0,080 µg/ml, respectively (Fig. 5B and 5C).
As the expression of HCV entry factors most probably differs between Huh-7 
cells and primary human hepatocytes, we repeated HCVpp neutralization 
experiments using primary hepatocytes. At least one antibody from each subject 
was selected for this experiment (AT1638, 1637, 1642, 1706 and 1618). As 
shown in Fig. 6A, at a concentration of 0.5µg/ml, all antibodies neutralized 
genotype 1a H77 HCVpp infection by more than 50% using primary hepatocytes. 
Moreover, AT1638, 1637 and 1642 also reduced the infection of AMS 3a.26 
HCVpp by more than 50% (Fig. 6B). Infection of AMS 3a.26 HCVpp was reduced 
by AT1706 and AT1618, however, by 25% to 50%. This reduction was consistent 
with data from the neutralization experiments using Huh-7 cells, where the IC50 
for AMS3a.26 HCVpp was respectively >1.36 and 1.64 µg/ml (Fig. 4B).
DISCUSSION
For the design of a protective HCV vaccine, a detailed understanding of the 
mechanism by which HCV infection is spontaneously cleared, is crucial. A strong 
and broad T cell response has been associated with clearance of HCV 
(re)infection [6,7]. However, the role of B cells producing HCV neutralizing 
antibody is largely undefined. Here, we studied the B-cell repertoire against HCV 
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E1E2 in a cohort of persistent IDU following clearance of primary HCV infection. 
We compared the breadth of the antibodies against E1E2 early after infection 
between subjects who were HCV RNA negative at the end of study follow-up 
(CLs) and subjects who ultimately became chronically infected (CHRs). Our main 
finding is that the frequency of B cells producing cross-genotype antibodies was 
significantly higher in CLs compared to CHRs. Moreover, in a subset of four CLs 
who we studied in more detail, we found that these cross-genotype antibodies 
mainly recognized AR3 and showed broad neutralizing activity. In addition, in 
three of these four CLs, we also identified cross-genotype antibodies targeting 
AR4.
The role of cross-neutralizing antibodies in protection against HCV infection in 
real-life settings has rarely been studied. Pestka et al. were the first to 
demonstrate that polyclonal serum neutralizing antibody responses were 
associated with spontaneous clearance of HCV infection [8]. Recently, it was 
shown, that cross-neutralization of a genotype 1 HCVpp panel by serum from 
subjects infected with genotype 1 and non-1 viruses, was associated with HCV 
clearance [9]. From two of these subjects, broadly neutralizing antibodies were 
isolated [34]. In the study presented here, a high frequency of B cells producing 
cross-genotype antibodies early after infection was associated with clearance of 
HCV infection. Moreover, in four of these subjects with such strong cross-
genotype B-cell response, we isolated broadly neutralizing antibodies. It is 
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tempting to hypothesize that these B cells expressing broadly neutralizing 
antibodies were induced during infection and contributed to viral clearance. 
It is important to note, however, that we do find variation in both breadth and 
frequency in the antibody responses between CL subjects. Subject CL5 for 
example presented only with genotype-specific antibodies, which could be due to 
the time point of PBMC selection or indicate that other components of the 
immune system such as T cells may have played a role in viral clearance. In 
addition to difference in breadth, we observed a relatively large difference in the 
frequency of E1E2 specific antibodies (IQR: 3.6 – 77 antibodies per 10,000 
antibodies). This could be a consequence of the time point of PBMC selection, 
natural inter-donor variation or technical issues.
The longitudinal design of our study allowed the selection of a subgroup of cohort 
participants (CLs) who never became chronically infected, despite presumably 
frequent re-exposure, since they continued injecting drugs during a long period in 
which incidence of infection was very high in IDU [20]. Indeed, in three of these 
CLs reinfections were documented after the time point of PBMC collection, even 
though HCV RNA testing, with a median of 11 HCV RNA tests per case [22], was 
not performed regularly enough to diagnose all reinfections [36]. Despite this 
assumed frequent re-exposure, CLs were HCV RNA negative at the end of a 
median follow-up of 17.7 years and developed memory B cells expressing 
broadly neutralizing antibodies. This finding is consistent with previous reports by 
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us and others describing memory B cells expressing broadly neutralizing 
antibodies from IDU who did not become chronically infected for more than 5 
years following clearance of primary infection [26,34]. Importantly, we also 
showed that such B-cell response can be long-lasting, since memory B cells 
expressing broadly neutralizing antibodies were circulating 25 years after 
clearance of the primary infection [26]. In this study, we confirm the longevity of 
memory AR3-specific B cells as these B-cells were still circulating 5.2 years after 
clearance of the primary infection in the CL3 subject (Supplementary Fig. 7). 
Taken together, this suggests that broadly neutralizing antibodies induced during 
primary infection, also contribute to the prevention of the subsequent chronic 
infections. However, such broadly neutralizing antibodies may not always provide 
sterilizing immunity, as indicated by the reinfections we observed in CLs.
The majority of antibodies with cross-reactivity against at least three genotypes, 
recognized AR3. From the four CLs with the largest number of HCV specific B 
cell cultures, we isolated eight AR3-specific monoclonal antibodies and 
confirmed their broadly neutralizing properties. This finding is consistent with 
other studies where AR3-specific antibodies have been isolated from subjects 
who cleared all infections [26,34]. The dominance of AR3-specific antibodies in 
the B-cell repertoire from CLs suggests that these antibodies play an important 
role in protection against HCV infection.
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Besides AR3-specific antibodies, we also detected cross-genotype antibodies 
targeting AR4. Little is known about AR4, since the focus has mainly been on the 
antibody AR4A [16]. While it has been suggested that AR4-specific antibodies 
are rare, we observed that 27 out of 113 (24%) cross-genotype antibodies 
targeted AR4, and that these antibodies were present in three of the four CLs. 
Although less abundant than AR3 antibodies, this suggests that AR4 targeting 
antibodies may be present in most subjects who develop cross-reactive 
antibodies. However, in contrast to the broad neutralization of AR4A, only one 
out of the four broadly reactive monoclonal AR4-specific antibodies isolated by 
us, showed broadly neutralizing capacity (AT1618). Consistent with previous 
observations for AR4A [16], we found that AR4-specific antibodies did not bind to 
soluble E2 ectodomain suggesting that AR4-specific antibodies only bind to the 
E1E2 complex or, alternatively, that differential conformation of soluble E2 
precludes the binding of AR4A-like antibodies. 
Several studies have shown that AR3- and AR4-specific antibodies act 
synergistically [16,37] and importantly, antibodies targeting AR3 (AR3A, AR3B) 
protected mice against HCV infection in combination with antibody AR4A [17]. In 
this light, our observation that three out of four CL subjects developed both AR3- 
and AR4-specific antibodies is interesting, since it may suggest a similarly 
combined neutralizing role of AR3 and AR4 specific antibodies in their clearance 
of HCV. If this is confirmed in future studies, a vaccine should induce antibodies 
against these two antigenic regions.
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Although we did not detect antibodies recognizing all genotypes in CHRs, others 
did isolate broadly reactive antibodies targeting AR3 from chronically infected 
subjects [15,38]. However, these antibodies were only found relatively late after 
infection. Here, we found that CLs had already developed B cells expressing 
cross-reactive antibodies within one year after acquiring HCV, while the CHRs at 
the same time point had mainly developed genotype-specific antibodies. This is 
in line with Osburn et al. who showed that the development of cross-reactive 
antibodies is delayed in chronically infected subjects [9]. Interestingly, one CHR 
(CHR2) had four cross-reactive antibodies which were specific for only 2 to 4 
genotypes (Figure 1B). We found that those cross-reactive antibodies targeted 
AR3 (Supplementary Fig. 8).Taken together, this suggests that in chronically 
infected individuals, AR3-specific antibody response may be too weak and/or 
may develop too late to prevent chronic infection. If confirmed, this means that a 
strong and broadly neutralizing antibody response should be established very 
early after infection in order to confer protection.
For the early development of cross-reactive antibodies, the host genetics may 
also be crucial since it was shown that early appearance of cross-reactive 
neutralizing antibodies was associated with two SNPs located upstream of the 
HLA-DQB1 and HLA-DQA2 genes [9]. 
In conclusion and to our best knowledge, this study describes for the first time, 
the B-cell repertoires against HCV E1E2 from subjects who spontaneously 
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cleared one or multiple infection(s) in comparison to subjects who ultimately 
developed a chronic infection. Our data suggest that an early and strong B-cell 
response inducing broadly neutralizing antibodies against AR3 and AR4, is 
important for viral clearance and prevention of subsequent chronic infections 
upon re-exposure. These observations permit cautious optimism that 
development of an effective preventive vaccine is feasible.
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Table
Table 1. Demographics and clinical characteristics 
Subject
ID
Type of 
HCV 
infection(
s)
Age*, 
(yr)
Gender
Follow-
up #, 
(yr)
Duration 
of 
injecting 
drug use#, 
(yr)
HCV sero-
conver-
sion 
Calendar 
year of 
infection
Timepoint 
of PBMC 
collection,
(yr)
CHR1
Chronic 
upon 
primary
34 M 12 4.4 Sc 1989 1.12 #
CHR2
Chronic 
upon 
primary
21 F 11 0.2 Sc 1988 1.18 #
CHR3
Chronic 
upon 
primary
47 M 17 11.9 Sc 1993 1.05 #
CHR4
Chronic 
upon 
reinfection
24 M 21 13.2 Rc 1989 0.81 #
CHR5
Chronic 
upon 
reinfection
29 F 18 4.9 Rc 1986
4.33#
1.19 $
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CL1
No 
reinfection
29 F 18 6.6 Rc 1992 0.47 #
CL2
Cleared 
multiple 
infections
23 F 17 7.5 Rc 1989 0.13 #
CL3
Cleared 
multiple 
infections
39 M 19 2.1 Sc 1990 0.43 #
CL4
Cleared 
multiple 
infections
20 F 19 5.3 Rc 1989 0.59 #
CL5
No 
reinfection
29 F 9 3.2 Rc 1988 0.75 #
CL7
Cleared 
multiple 
infections
23 M 23 14.5 Rc 1986
9.36#,
2.51 $
CL8
Cleared 
multiple 
infections
33 F 14 6.4 Rc 1989
0.93#,
0.59 $
CL9
Cleared 
multiple 
infections
26 M 7 4.9 Rc 1987
5.28#,
0.54 $
Median 29 17.5 5.3 1989 0.75
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CHR: Subjects who ultimately became chronically infected; CL: Subjects who, at 
the end of study follow-up, were HCV RNA negative; Chronic upon primary: 
subjects who became chronically infected following primary infection; Chronic 
following reinfection: subjects who became chronically infected following 
reinfection; Cleared multiple infections: subjects who spontaneously cleared both 
primary infection and reinfection; No reinfection: subjects who spontaneously 
cleared primary infection without a documented reinfection; yr, years; F, female; 
M, male; Sc, seroconverter; Rc, recent; yr,years; *, at the estimated date of 
infection, #: after the estimated date of infection and $, after estimated time of 
reinfection
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Figure legends
Fig. 1. Frequency and cross-reactivity of E1E2 specific antibodies.
The number and the cross-reactivity of E1E2 specific antibodies were studied in 
subjects ultimately chronically infected (CHR) or in subjects who, at the end of 
study follow-up, were HCV RNA negative (CL). Antibodies present in B cell 
supernatant of 35 cell per well mini-cultures (total of 10,290 CD27+IgG+ B cells) 
were tested for binding to E1E2 derived from 6 different genotypes using a 
multiplexed flow cytometry assay. (A) From each subject (in row), the number 
and frequency of antibodies specific for E1E2 from genotype 1 to 6 / isolate (in 
column) are indicated. The grey filling colours indicate the number of E1E2 
antibodies targeting E1E2 of a particular genotype: white indicates the lowest 
number of antibodies and grey dark the highest. For each subject, the highest 
number of antibodies binding E1E2 from a particular genotype was bolded and 
underlined. NA: Not Applicable; ND: Not Determined. (B) The pie chart with grey 
scale represents cross-reactivity of the E1E2 specific antibodies from each 
subject.
Fig. 2. Epitope binding of the cross-genotype antibodies from CL subjects.
To determine the epitopes targeted by the cross-genotype antibodies, antibody 
binding was tested by ELISA using E1E2 mutants. Single alanine amino acid 
substitutions were introduced in the E1E2 sequence from isolate H77 at positions 
important for binding of broadly neutralizing antibodies in four described epitopes 
(epitope I, AR3 / epitope II, domain B and AR4). Cell lysates from 293T cells 
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transfected with the alanine-mutants of E1E2 were incubated on Galanthus 
nivalis lectin pre-coated wells before the antibodies containing B cell 
supernatants from subjects CL1, CL2, CL3 and CL7 were added. From the 
optical density value of each well the background was subtracted, and the 
relative binding was calculated by dividing the value obtained on wild-type protein 
by the alanine-mutant protein value. (A) The pie charts represent the distribution 
of epitopes targeted by all cross-genotype specific antibodies from each subject 
separately. (B) The colour filling indicates the relative binding level: black 0% - 
25%, grey 25-50% and white 50% -150%. The E2 mutants were designated 
X123Y where 123 is the residue position, X is the wild-type amino acid residue in 
H77 and Y indicates the replacing amino acid. The data are the mean values of 
two experiments performed in duplicate.
Fig. 3. Characteristics of monoclonal cross-genotype antibodies from CL 
subjects.
(A) Shown are antibody heavy and light chain genes of ten B cell clones that 
were isolated by single cell sorting of B cells from subjects CL1, CL2, CL3 and 
CL7, and two B cell clones (AT1706 and AT1618) from subject CL7 that were 
obtained after screening single B cell cultures for HCVpp neutralization activity. 
Gene analysis was done using the IMGT/V-QUEST database. VH: variable 
domain of the heavy chain, VL: variable domain of the light chain, CDR: 
complementarity determining region, aa: amino acids. (B) The cross-reactivity of 
the twelve monoclonal antibodies was confirmed by ELISA. First, the cell lysates 
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of 293T cells transfected with E1E2 from genotype 1 to 6 or non-transfected cells 
were captured on GNA pre-coated wells before antibodies present in B cell 
supernatants were added and detected using anti-human IgG conjugated 
horseradish peroxidase. The x-axis indicates the mean optical density (OD) at 
450nm and the errors bars represent one standard deviation. Anti-RSV F 
antibody D25 was used as a negative control and anti-HCV AT12-009 as a 
positive control. The assay was performed in duplicate wells and repeated at 
least once.
Fig. 4. Neutralization activity of cross-genotype antibodies from CL 
subjects in HCV pseudotyped particles (pp) system. 
The neutralization capacity of the antibodies was tested using (A-B) a panel of 
four HCVpp from genotypes 1 to 4 and (C-D) a panel of four HCVpp resistant to 
antibody neutralization genotype 2 to 6. Neutralization was determined by 
incubating HCVpp expressing E1E2 with a two-fold serial dilution of antibody-
containing B cell supernatants before inoculation of Huh-7 cells. The 50% 
inhibitory concentration (IC50 in µg/mL) was determined as the midpoint between 
the last concentration giving more than 50% neutralization and the first 
concentration giving less than 50% neutralization. The grey colours indicate the 
range of neutralization: an IC50 <0.1 µg/mL (black), 0.1–1 µg/mL (dark grey), 1–
10 µg/mL (light grey) and above 10µg/ml or no 50% neutralization was observed 
(white). ND: not done. The genotype of the isolates is indicated between 
brackets.
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Fig. 5. Neutralization activity of cross-genotype antibodies from CL 
subjects in HCV cell culture (cc) system. 
(A) Neutralization was determined by incubating HCVcc expressing E1E2 from 
isolate H77 with 20µg/mL of purified antibodies before inoculation of Huh-7.5 
cells. Percentage of neutralization was determined by comparison to the number 
of cells infected in the absence of antibodies. Anti-tetanus toxin antibody was 
used as a negative control and anti-HCV AR3B as a positive control. (B) 
Neutralization potency of AT1618 was determined by incubating HCVcc 
expressing E1E2 isolate JFH-1 (genotype 2a) and ED43 (genotype 4a) with a 
four-fold serial dilutions of purified antibody starting 50µg/ml before inoculation of 
Huh-7.5 cells. The neutralization percentage was determined by the reduction in 
luciferase activity compared to background and no antibody samples. 50% 
inhibitory concentrations (IC50 in μg/mL) were determined using non-linear 
regression analysis. Anti-HIV antibody 3BNC60 was used as a negative control 
and anti-HCV AR4A as a positive control. ND: not done. The errors bars 
represent one standard deviation (SD).
Fig. 6. AT antibodies to block entry of HCV into primary hepatocytes. 
The neutralization capacity of the antibodies was tested using HCVpp derived 
from (A) H77 HCV isolate (genotype 1), or (B) AMS3a.26 HCV isolate (genotype 
3). HCVpp supernatants were incubated with 0.5 µg/mL antibody-containing B 
cell supernatants before being inoculated onto primary human hepatocytes 
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seeded the day before. After three days, the luciferase activity was measured 
using an EnVision® Multilabel Reader. The anti-RSV F antibody (D25) was used 
as a negative control. The y-axis indicates the mean relative light units and the 
errors bars represent one SD. The grey dotted line depicts 50% of infection 
based on the negative control.
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Highlights
 HCV clearance is associated with high number of cross-genotype specific 
antibodies.
 Antigenic region 3 (AR3) is the dominant epitope recognized by the 
antibodies.
 AR3-specific antibodies neutralized HCV pseudoparticles and cell culture 
viruses.
 A large number of clearers develop antibodies targeting antigenic region 4 
(AR4).
 AR4-specific antibody AT1618 also neutralized neutralization-resistant 
variants.
